In high-risk patients, cisplatin may enhance antigen presentation by dendritic cells via the release of immune-stimulatory molecules such as calreticulin (CRT) and HMGB1, thereby activating T-cell-mediated anti-tumor responses (Ma et al., 2025; Yasuda et al., 2025). Here, HMGB1 is linked to neoplasm.